RhumbLine Advisers’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-2,480
| Closed | -$37.5K | – | 4423 |
|
|
2024
Q2 | $37.5K | Sell |
2,480
-11,039
| -82% | -$164K | ﹤0.01% | 3757 |
|
|
2024
Q1 | $200K | Sell |
13,519
-432
| -3% | -$6.07K | ﹤0.01% | 3178 |
|
|
2023
Q4 | $187K | Buy |
13,951
+72
| +0.5% | +$910 | ﹤0.01% | 3221 |
|
|
2023
Q3 | $171K | Buy |
13,879
+1,313
| +10% | +$15.9K | ﹤0.01% | 3242 |
|
|
2023
Q2 | $155K | Buy |
+12,566
| New | +$157K | ﹤0.01% | 3366 |
|
|
2018
Q2 | – | Sell |
-15,121
| Closed | -$96K | – | 2995 |
|
|
2018
Q1 | $96K | Sell |
15,121
-356
| -2% | -$2.95K | ﹤0.01% | 2742 |
|
|
2017
Q4 | $125K | Sell |
15,477
-3,155
| -17% | -$29.4K | ﹤0.01% | 2744 |
|
|
2017
Q3 | $213K | Buy |
18,632
+191
| +1% | +$2.01K | ﹤0.01% | 2702 |
|
|
2017
Q2 | $180K | Buy |
18,441
+573
| +3% | +$11.7K | ﹤0.01% | 2793 |
|
|
2017
Q1 | $433K | Buy |
17,868
+597
| +3% | +$14.9K | ﹤0.01% | 2316 |
|
|
2016
Q4 | $554K | Buy |
17,271
+397
| +2% | +$16.9K | ﹤0.01% | 2172 |
|
|
2016
Q3 | $843K | Sell |
16,874
-127
| -0.7% | -$5.27K | ﹤0.01% | 1914 |
|
|
2016
Q2 | $721K | Buy |
17,001
+2,353
| +16% | +$128K | ﹤0.01% | 1978 |
|
|
2016
Q1 | $965K | Buy |
14,648
+424
| +3% | +$22.1K | ﹤0.01% | 1823 |
|
|
2015
Q4 | $884K | Buy |
14,224
+1,219
| +9% | +$85.8K | ﹤0.01% | 1891 |
|
|
2015
Q3 | $871K | Buy |
13,005
+62
| +0.5% | +$5.06K | ﹤0.01% | 1855 |
|
|
2015
Q2 | $1.26M | Buy |
12,943
+596
| +5% | +$56.7K | ﹤0.01% | 1719 |
|
|
2015
Q1 | $1.15M | Buy |
12,347
+2,003
| +19% | +$170K | ﹤0.01% | 1767 |
|
|
2014
Q4 | $920K | Buy |
10,344
+14
| +0.1% | +$1.02K | ﹤0.01% | 1872 |
|
|
2014
Q3 | $714K | Buy |
10,330
+114
| +1% | +$6.09K | ﹤0.01% | 1990 |
|
|
2014
Q2 | $586K | Buy |
10,216
+586
| +6% | +$29.8K | ﹤0.01% | 2170 |
|
|
2014
Q1 | $382K | Sell |
9,630
-562
| -6% | -$24K | ﹤0.01% | 2390 |
|
|
2013
Q4 | $428K | Sell |
10,192
-420
| -4% | -$12.2K | ﹤0.01% | 2354 |
|
|
2013
Q3 | $317K | Buy |
10,612
+383
| +4% | +$13.4K | ﹤0.01% | 2495 |
|
|
2013
Q2 | $542K | Buy |
+10,229
| New | +$448K | ﹤0.01% | 2191 |
|
RhumbLine Advisers's MACK Position: Q3 2024 in Review
RhumbLine Advisers sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2024, closing a stake of 2,480 shares — an estimated $37.5K sold.
RhumbLine Advisers first reported a position in MACK in Q2 2013 and held it in 25 quarters. The position peaked at $1.26M in Q2 2015. 2 funds tracked by Wall St. Rank hold MACK as of Q3 2024.
- RhumbLine Advisers reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2024 after selling out during the quarter.
- RhumbLine Advisers sold 2,480 Merrimack Pharmaceuticals, Inc. shares in Q3 2024, an estimated $37.5K.
- RhumbLine Advisers first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 25 quarters.
- RhumbLine Advisers's Merrimack Pharmaceuticals, Inc. position peaked at $1.26M in Q2 2015.
- 2 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2024.
Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.